Raloxifene/Cholecalciferol- Alvogen Korea

Drug Profile

Raloxifene/Cholecalciferol- Alvogen Korea

Alternative Names: DP R213; Raloxifene/Cholecalciferol

Latest Information Update: 21 Jan 2017

Price : $50

At a glance

  • Originator Alvogen Korea
  • Class Adjuvants; Antineoplastics; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Stilbenes; Vitamin D analogues
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Fracture; Postmenopausal osteoporosis; Vitamin D deficiency

Most Recent Events

  • 01 Jan 2017 Preclinical trials in Breast cancer in South Korea (unspecified route) before January 2017 (NCT03010267)
  • 01 Jan 2017 Preclinical trials in Fracture in South Korea (unspecified route) before January 2017 (NCT03010267)
  • 01 Jan 2017 Preclinical trials in Postmenopausal osteoporosis in South Korea (unspecified route) before January 2017 (NCT03010267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top